BTIG initiated coverage of Moonlake Immunotherapeutics (NASDAQ:MLTX) with a “buy” rating and $36 price target. The stock closed at $23.70 on March 8. “We see Moonlake’s sonelokimab (SLK) well-positioned to emerge as the...
Echelon Capital Markets initiated coverage of Valeo Pharma (TSX:VPH) with a “speculative buy” rating and price target of $1 (Canadian). The stock closed at 55 cents on March 8. Valeo commercializes de-risked, innovative...
Raymond James raised its price target for Profound Medical (NASDAQ:PROF) to $17 from $15 and reiterated a “strong buy” rating after the company said its application for full CPT-1 reimbursement for TULSA-PRO has been...
Stifel launched coverage of Mineralys Therapeutics (NASDAQ:MLYS) with a “buy” rating and 12-month price target of $45. The stock closed at $18.96 on March 7. Mineralys’ lorundrostat is targeting hyperaldosteronism, a...
SVB Securities initiated coverage of Structure Therapeutics (NASDAQ:GPCR) with an “outperform” rating and $33 price target. The stock closed at $24 on Feb. 27. “Our investment thesis is that the company’s platform and...
SVB Securities launched coverage of Disc Medicine (NASDAQ:IRON) with an “outperform” rating and $36 price target. The stock closed at $24.39 on Feb. 27. Disc Medicine is a clinical-stage biopharmaceutical company...
Piper Sandler launched coverage of Orchestra Biomed (NASDAQ:OBIO) with an “overweight” rating and $15 price target. The stock closed at $10.30 on Feb. 23. The company develops solutions in cardiac neuromodulation and...
Research Capital likes the potential chances of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar photodynamic therapy being better than Merck’s Keytruda for treating Bacillus Calmette-Guérin (BCG)-unresponsive...
Dawson James Securities initiated coverage of Hillstream BioPharma (NASDAQ:HILS) with a “buy” rating and price target of $4. The stock closed at $1.24 on Feb. 21. Hillstream is a preclinical biotechnology company...
Alliance Global Partners initiated coverage of CollPlant Biotechnologies (NASDAQ:CLGN) with a “buy” rating and price target of $22.75. The stock closed at $11.80 on Feb. 16. CollPlant has developed a proprietary method...